Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A Review
Isabelle House, Mari Valore-Caplan, Elijah Maris, Gerald S. Falchook
Abstract
Cyclin dependent kinase 2 (CDK2) is responsible for enforcing progression through the G1-S phase transition. Mutations and alterations in the CDK2 signaling pathway are associated with various cancers, most commonly breast, ovarian, prostate, leukemia, and lymphoma. CDK2 inhibitors have shown promising preclinical and early clinical results, and this class of agents may be most effective against cancers with cyclin E overactivity. Common side effects observed include nausea, vomiting, diarrhea, anemia, and fatigue. This clinical review summarizes past and current CDK2 inhibitors in clinical trials.
Topics & Concepts
Cyclin-dependent kinase 2MedicineCyclin-dependent kinaseCancer researchNauseaInternal medicineOncologyCyclin EVomitingCell cycleCancerAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysPancreatic and Hepatic Oncology Research